Table 1. Patient demographics and baseline characteristics.
Category | N = 177 | |
---|---|---|
n | (%) | |
Sex | ||
Male | 102 | (57.6) |
Female | 75 | (42.4) |
Age (years) | ||
Median (range) | 71 (48–86) | |
≥ 75 years | 39 | (22.0) |
Type of myeloma | ||
IgG | 108 | (61.0) |
IgA | 43 | (24.3) |
IgM | 2 | (1.1) |
Light chain | 20 | (11.3) |
Non-secretory | 4 | (2.3) |
Stage - Durie–Salmon Staging System | ||
I | 13 | (7.3) |
II | 51 | (28.8) |
III | 113 | (63.8) |
Stage - International Staging System | ||
I | 22 | (12.6) |
II | 70 | (40.0) |
III | 83 | (47.4) |
Skeletal lesions | ||
0 | 33 | (18.6) |
1–2 | 44 | (24.9) |
≥ 3 | 80 | (45.2) |
Unknown | 20 | (11.3) |
ECOG-PS | ||
0 | 11 | (6.2) |
1 | 104 | (58.8) |
2 | 42 | (23.7) |
3 | 19 | (10.7) |
4 | 1 | (0.6) |
Serum β2-microglobulin (mg/L) | ||
Median (range) | 5.3 (0–35.3) | |
< 2.5 | 17 | (9.7) |
2.5–5.5 | 75 | (42.9) |
> 5.5 | 83 | (47.4) |
Albumin (g/dL) | ||
Median (range) | 3.3 (1.0–5.1) | |
< 3.5 | 107 | (61.1) |
≥ 3.5 | 68 | (38.9) |
Creatinine clearance (mL/min) | ||
Median (range) | 43.6 (5.8–106.6) | |
< 60 | 129 | (73.7) |
≥ 60 | 46 | (26.3) |
Comorbidity | ||
No | 40 | (22.6) |
Yesb | 137 | (77.4) |
Allergy | 1 | (0.6) |
Renal impairment | 31 | (17.5) |
Hepatic impairment | 5 | (2.8) |
Others | 129 | (72.9) |
Cytogenetics abnormality category | ||
Standard risk | 121 | (68.4) |
High riska | 24 | (13.6) |
Deletion 13 by karyotypeb | 17 | (9.6) |
Deletion 17p by FISHb | 7 | (4.0) |
t(4:14) by FISHb | 6 | (3.4) |
t(14:16) by FISHb | 4 | (2.3) |
Hypodiploidy by karyotypeb | 2 | (1.1) |
Test not done | 32 | (18.1) |
a High risk cytogenetics: deletion 13 by karyotype, deletion 17p by FISH/karyotype, t(4;14), t(14;16), and hypodiploidy.
b Multiple counting.
FISH, fluorescence in situ hybridization.